fbpx Skip to main content

Member's Profile

CeleCor Therapeutics

1155 Camino Del Mar, Suite 481
Del Mar,   California
United States
Membership Info
Membership Type: Industry
Membership Since: 2017
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About CeleCor Therapeutics
Biotech Company
We are continuing the development of RUC-4, a novel small molecule inhibitor of the platelet αIIbβ3 receptor, designed to be easily administered subcutaneously by auto-injector to facilitate its use as the first point of contact treatment for myocardial infarction (STEMI). 
Related News
No related news posted by this Member